{"id":"melflufen","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Breastfeeding (mother)"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT06682637","NCT04412707","NCT04649060","NCT02963493","NCT01897714","NCT04115956","NCT03151811","NCT04534322","NCT03481556","NCT03639610"],"aliases":["Melphalan Flufenamide","Pepaxto","Pepaxti","Melphalan flufenamide"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Melflufen","companyId":"oncopeptides-ab","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Oncopeptides AB","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Melflufen","indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma","diseaseId":"relapsed-or-refractory-multiple-myeloma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06682637","phase":"Phase 2","title":"Melflufen for Elderly Myeloma Patients in Second or Subsequent Relapse","status":"WITHDRAWN","sponsor":"Fondazione EMN Italy Onlus","isPivotal":false,"enrollment":0,"indication":"Relapse Multiple Myeloma","completionDate":"2025-03-26"},{"nctId":"NCT04412707","phase":"Phase 2","title":"A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen","status":"TERMINATED","sponsor":"Oncopeptides AB","isPivotal":false,"enrollment":27,"indication":"RRMM","completionDate":"2022-01-10"},{"nctId":"NCT04649060","phase":"Phase 3","title":"A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Oncopeptides AB","isPivotal":true,"enrollment":54,"indication":"Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma","completionDate":"2022-02-07"},{"nctId":"NCT02963493","phase":"Phase 2","title":"A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Mono","status":"COMPLETED","sponsor":"Oncopeptides AB","isPivotal":false,"enrollment":157,"indication":"Multiple Myeloma","completionDate":"2021-11-16"},{"nctId":"NCT01897714","phase":"Phase 1","title":"An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Oncopeptides AB","isPivotal":false,"enrollment":75,"indication":"Relapsed and/or Relapsed-refractory Multiple Myeloma","completionDate":"2020-03"},{"nctId":"NCT04115956","phase":"Phase 1","title":"An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy","status":"TERMINATED","sponsor":"Oncopeptides AB","isPivotal":false,"enrollment":6,"indication":"AL Amyloidosis","completionDate":"2022-01-05"},{"nctId":"NCT03151811","phase":"Phase 3","title":"A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Len","status":"TERMINATED","sponsor":"Oncopeptides AB","isPivotal":true,"enrollment":495,"indication":"Multiple Myeloma","completionDate":"2023-02-03"},{"nctId":"NCT04534322","phase":"N/A","title":"An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma","status":"APPROVED_FOR_MARKETING","sponsor":"Oncopeptides AB","isPivotal":false,"enrollment":0,"indication":"Relapsed and/or Refractory Multiple Myeloma","completionDate":""},{"nctId":"NCT03481556","phase":"Phase 1","title":"An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple ","status":"TERMINATED","sponsor":"Oncopeptides AB","isPivotal":false,"enrollment":56,"indication":"Multiple Myeloma","completionDate":"2022-02-02"},{"nctId":"NCT03639610","phase":"Phase 2","title":"A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function","status":"TERMINATED","sponsor":"Oncopeptides AB","isPivotal":false,"enrollment":35,"indication":"Renal Impairment, Multiple Myeloma","completionDate":"2021-12-22"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}